Mayo Clinic researchers have developed a pioneering strategy to improve targeted cancer therapies. "The ability to target specific proteins and improve drug absorption into tumor cells represents a significant step forward in how we approach aggressive cancers," says Aaron Mansfield, M.D., a medical oncologist and lead author of the study at the Center for Individualized Medicine and the Mayo Clinic Comprehensive Cancer Center. Learn more: https://mayocl.in/3WyEFAQ
Mayo Clinic’s Post
More Relevant Posts
-
Did you know? Liver cancer incidence rates have more than tripled since 1980? The American Cancer Society estimates about 41,630 adults in the United States will be diagnosed with primary #livercancer in 2024. Through our advancement in biomarker research and testing, Fujifilm is continuing to raise awareness around early detection of Hepatocellular carcinoma (HCC) - the most common type of primary liver cancer. Learn more about our serum biomarkers and the work our In Vitro Diagnostics division is doing here: https://brnw.ch/21wOeCL #LiverCancerAwarenessMonth
-
-
The Masters in Thoracic Oncology Summit | MaTOS is a 3-day meeting, presented in significant distinct sessions by key thoracic oncology experts. This summit will address and discuss the current challenges and future directions in the lung cancer space. Through open discussions we will have the opportunity to analyze the latest discoveries in genetics and epigenomics in lung cancer, including diagnosis, minimal residual disease (MRD), monitoring for recurrence, and assessment of therapeutic success with targeted therapy and immunotherapy. #lungcancer #lcsm
-
-
SALES EXECUTIVE - BUSINESS DEVELOPMENT - RELATIONSHIP MANAGEMENT - OPERATIONS LEADERSHIP - ELEVATING BUSINESS PERFORMANCE - EXPEDITING GROWTH AND PROFITABILITY
In this molecular tumor board series, Dr. Marcela Mazo Canola, a breast medical oncologist, joined us to discuss the importance of biomarker testing for therapeutic implications in metastatic breast cancer. We discussed two cases of metastatic hormone receptor-positive (HR+), HER2-negative breast cancer with PIK3CA and AKT1 alterations. We reviewed the pivotal clinical trials leading to the approval of targeted therapies for these alterations, as well as side effect profiles and testing workflows for biomarker-guided therapy in HR+ breast cancer. Learn more: #BreastCancer #MetastaticBreastCancer
-
-
This September we recognize National Prostate Cancer Awareness Month. Did you know that a man is more likely to develop prostate cancer than he is to develop colon, kidney, melanoma, and stomach cancers combined?* Philips Ultrasound supports physicians, patients, and their families with innovative solutions to help aid the diagnosis, monitoring and treatment of prostate cancer. #Ultrasound #ProstateCancerAwarenessMonth *Prostate Cancer Foundation (2024). Top 10 things you should know about prostate cancer. https://lnkd.in/eMBmi6Sd Learn More: https://lnkd.in/e48SXW8G
-
-
Precision Medicine I Pharma/Biotech I Global Strategic Partnering I Biomarker Discovery I Drug Development I Clinical Trials I Oncology Therapeutics I Cell & Gene Therapy I Companion Diagnostics Commercialization
In this molecular tumor board series, Dr. Marcela Mazo Canola, a breast medical oncologist, joined us to discuss the importance of biomarker testing for therapeutic implications in metastatic breast cancer. We discussed two cases of metastatic hormone receptor-positive (HR+), HER2-negative breast cancer with PIK3CA and AKT1 alterations. We reviewed the pivotal clinical trials leading to the approval of targeted therapies for these alterations, as well as side effect profiles and testing workflows for biomarker-guided therapy in HR+ breast cancer. Learn more: https://lnkd.in/eU-g3T3d #BreastCancer #MetastaticBreastCancer
-
-
In this molecular tumor board series, Dr. Marcela Mazo Canola, a breast medical oncologist, joined us to discuss the importance of biomarker testing for therapeutic implications in metastatic breast cancer. We discussed two cases of metastatic hormone receptor-positive (HR+), HER2-negative breast cancer with PIK3CA and AKT1 alterations. We reviewed the pivotal clinical trials leading to the approval of targeted therapies for these alterations, as well as side effect profiles and testing workflows for biomarker-guided therapy in HR+ breast cancer. Learn more: https://lnkd.in/gvsFv2Cr #BreastCancer #MetastaticBreastCancer
-
-
Vice President and Enterprise Head of Cell and Gene Therapy at Labcorp Drug Development
In this molecular tumor board series, Dr. Marcela Mazo Canola, a breast medical oncologist, joined us to discuss the importance of biomarker testing for therapeutic implications in metastatic breast cancer. We discussed two cases of metastatic hormone receptor-positive (HR+), HER2-negative breast cancer with PIK3CA and AKT1 alterations. We reviewed the pivotal clinical trials leading to the approval of targeted therapies for these alterations, as well as side effect profiles and testing workflows for biomarker-guided therapy in HR+ breast cancer. Learn more: https://lnkd.in/eH2yX2Gw #BreastCancer #MetastaticBreastCancer
-
-
Just One Month Away! Join us at the Masters in Thoracic Oncology Summit (MaTOS) on November 21-24, 2024, for three transformative days with leading experts in lung cancer. This summit will tackle the latest challenges and future directions in thoracic oncology, diving into key topics like genetics, minimal residual disease (MRD), monitoring for recurrence, and assessing therapeutic success with targeted therapies and immunotherapy. Don't miss your chance to engage in open discussions and stay at the forefront of lung cancer research! 👉 Register now at matos-lung.com! #MaTOS #ThoracicOncology #LungCancer #MedicalSummit #CancerResearch #RegisterNow
-
-
In this molecular tumor board series, Dr. Marcela Mazo Canola, a breast medical oncologist, joined us to discuss the importance of biomarker testing for therapeutic implications in metastatic breast cancer. We discussed two cases of metastatic hormone receptor-positive (HR+), HER2-negative breast cancer with PIK3CA and AKT1 alterations. We reviewed the pivotal clinical trials leading to the approval of targeted therapies for these alterations, as well as side effect profiles and testing workflows for biomarker-guided therapy in HR+ breast cancer. Learn more: https://lnkd.in/ecduEyiy #BreastCancer #MetastaticBreastCancer
-
-
In this molecular tumor board series, Dr. Marcela Mazo Canola, a breast medical oncologist, joined us to discuss the importance of biomarker testing for therapeutic implications in metastatic breast cancer. We discussed two cases of metastatic hormone receptor-positive (HR+), HER2-negative breast cancer with PIK3CA and AKT1 alterations. We reviewed the pivotal clinical trials leading to the approval of targeted therapies for these alterations, as well as side effect profiles and testing workflows for biomarker-guided therapy in HR+ breast cancer. Learn more: https://lnkd.in/gevpU5Di #BreastCancer #MetastaticBreastCancer
-
CEO @ Amarastesia | Board Certified Anesthesiologist, Lead Innovator
1moAdvanced research into early metastasis and attraction of invasive tumor cell lines into a targeted lock and kill mechanism is a topic I'm currently working on. If interested in collaboration please D.M. me.